Jianwen Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jianwen Zhou has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Cuicui Han
College of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China
1 shared publication - Haijun Wang
College of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China
1 shared publication - Haoyi Zhao
College of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China
1 shared publication Honglian Zhang
College of Pharmacy, Qiqihar Medical University
1 shared publication- Jiale Wu
College of Pharmacy, Hainan University, Haikou 570228, China
1 shared publication Jicheng Liu
College of Pharmacy, Qiqihar Medical University
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1880993
Calycosin alleviates myocardial injury in diabetic mice by enhancing lipophagy in cardiomyocytes via Rab7a regulation
Background: Diabetic cardiomyopathy (DCM) is a major life-threatening cardiovascular complication of diabetes mellitus, characterized by myocardial lipid deposition, lipotoxicity and progressive cardiac dysfunction. Impaired lipophagy—the selective autophagic clearance of lipid droplets (LDs)—is a key driver of DCM progression, and Rab7a, a small GTPase, is essential for autophagosome–lysosome fusion, the rate-limiting step of efficient lipophagic degradation. Calycosin (CA), a natural isoflavone derived from Astragalus membranaceus , exerts antidiabetic and cardioprotective effects. However, whether CA regulates lipophagy via Ras-related protein Rab-7a (Rab7a) to ameliorate DCM remains largely unknown. The present study investigated whether CA alleviates DCM by promoting lipophagy through Rab7a-dependent mechanisms. Methods: In vivo , DCM was induced in male C57BL/6J mice by a high-fat diet combined with low-dose streptozotocin (STZ), followed by daily CA administration. In vitro , neonatal mouse cardiomyocytes (NMCMs) were isolated and exposed to high glucose and high lipid (HGHL) conditions to mimic the DCM microenvironment. Cardiac function was assessed by echocardiography. Myocardial lipid accumulation was evaluated by Oi-Red O staining, Bodipy staining and triglyceride (TG) quantification assay. Lipophagy was monitored using transmission electron microscopy (TEM), LC3-LD colocalization analysis and Western blotting. Rab7a was knocked down in NMCMs using specific small interfering RNAs (siRNAs), and its ubiquitination level was detected by co-immunoprecipitation (Co-IP) assay. Results: CA significantly improved cardiac function, reduced myocardial fibrosis and lipid accumulation, and restored impaired lipophagic flux in DCM mice. Consistently, in HGHL-stimulated NMCMs, CA promoted lipophagy and suppressed lipotoxic injury. Mechanistically, CA upregulated Rab7a protein expression and inhibited its ubiquitination. Rab7a knockdown abolished CA-mediated lipophagy activation and subsequent lipid clearance. Conclusion: CA enhances cardiomyocyte lipophagy by upregulating Rab7a and suppressing its ubiquitination, thereby mitigating excessive lipid deposition and subsequent myocardial injury in DCM mice. These findings reveal a novel mechanism by which CA regulates cardiomyocyte lipophagy and highlight Rab7a-mediated lipophagy as a promising therapeutic target for diabetic cardiac lipotoxicity.
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1880993
Open AccessCalycosin alleviates myocardial injury in diabetic mice by enhancing lipophagy in cardiomyocytes via Rab7a regulation
Background: Diabetic cardiomyopathy (DCM) is a major life-threatening cardiovascular complication of diabetes mellitus, characterized by myocardial lipid deposition, lipotoxicity and progressive cardiac dysfunction. Impaired lipophagy—the selective autophagic clearance of lipid droplets (LDs)—is a key driver of DCM progression, and Rab7a, a small GTPase, is essential for autophagosome–lysosome fusion, the rate-limiting step of efficient lipophagic degradation. Calycosin (CA), a natural isoflavone derived from Astragalus membranaceus , exerts antidiabetic and cardioprotective effects. However, whether CA regulates lipophagy via Ras-related protein Rab-7a (Rab7a) to ameliorate DCM remains largely unknown. The present study investigated whether CA alleviates DCM by promoting lipophagy through Rab7a-dependent mechanisms. Methods: In vivo , DCM was induced in male C57BL/6J mice by a high-fat diet combined with low-dose streptozotocin (STZ), followed by daily CA administration. In vitro , neonatal mouse cardiomyocytes (NMCMs) were isolated and exposed to high glucose and high lipid (HGHL) conditions to mimic the DCM microenvironment. Cardiac function was assessed by echocardiography. Myocardial lipid accumulation was evaluated by Oi-Red O staining, Bodipy staining and triglyceride (TG) quantification assay. Lipophagy was monitored using transmission electron microscopy (TEM), LC3-LD colocalization analysis and Western blotting. Rab7a was knocked down in NMCMs using specific small interfering RNAs (siRNAs), and its ubiquitination level was detected by co-immunoprecipitation (Co-IP) assay. Results: CA significantly improved cardiac function, reduced myocardial fibrosis and lipid accumulation, and restored impaired lipophagic flux in DCM mice. Consistently, in HGHL-stimulated NMCMs, CA promoted lipophagy and suppressed lipotoxic injury. Mechanistically, CA upregulated Rab7a protein expression and inhibited its ubiquitination. Rab7a knockdown abolished CA-mediated lipophagy activation and subsequent lipid clearance. Conclusion: CA enhances cardiomyocyte lipophagy by upregulating Rab7a and suppressing its ubiquitination, thereby mitigating excessive lipid deposition and subsequent myocardial injury in DCM mice. These findings reveal a novel mechanism by which CA regulates cardiomyocyte lipophagy and highlight Rab7a-mediated lipophagy as a promising therapeutic target for diabetic cardiac lipotoxicity.
- Open Access
Discovery and Optimization of Ergosterol Peroxide Derivatives as Novel Glutaminase 1 Inhibitors for the Treatment of Triple-Negative Breast Cancer
In this study, novel ergosterol peroxide (EP) derivatives were synthesized and evaluated to assess their antiproliferative activity against four human cancer cell lines (A549, HepG2, MCF-7, and MDA-MB-231). Compound 3g exhibited the most potent antiproliferative activity, with an IC50 value of 3.20 µM against MDA-MB-231. This value was 5.4-fold higher than that of the parental EP. Bioassay optimization further identified 3g as a novel glutaminase 1 (GLS1) inhibitor (IC50 = 3.77 µM). In MDA-MB-231 cells, 3g reduced the cellular glutamate levels by blocking the glutamine hydrolysis pathway, which triggered reactive oxygen species production and induced caspase-dependent apoptosis. Molecular docking indicated that 3g interacts with the reaction site of the variable binding pocket by forming multiple interactions with GLS1. In a mouse model of breast cancer, 3g showed remarkable therapeutic effects at a dose of 50 mg/kg, with no apparent toxicity. Based on these results, 3g could be further evaluated as a novel GLS1 inhibitor for triple-negative breast cancer (TNBC) therapy.
Open AccessDiscovery and Optimization of Ergosterol Peroxide Derivatives as Novel Glutaminase 1 Inhibitors for the Treatment of Triple-Negative Breast Cancer
In this study, novel ergosterol peroxide (EP) derivatives were synthesized and evaluated to assess their antiproliferative activity against four human cancer cell lines (A549, HepG2, MCF-7, and MDA-MB-231). Compound 3g exhibited the most potent antiproliferative activity, with an IC50 value of 3.20 µM against MDA-MB-231. This value was 5.4-fold higher than that of the parental EP. Bioassay optimization further identified 3g as a novel glutaminase 1 (GLS1) inhibitor (IC50 = 3.77 µM). In MDA-MB-231 cells, 3g reduced the cellular glutamate levels by blocking the glutamine hydrolysis pathway, which triggered reactive oxygen species production and induced caspase-dependent apoptosis. Molecular docking indicated that 3g interacts with the reaction site of the variable binding pocket by forming multiple interactions with GLS1. In a mouse model of breast cancer, 3g showed remarkable therapeutic effects at a dose of 50 mg/kg, with no apparent toxicity. Based on these results, 3g could be further evaluated as a novel GLS1 inhibitor for triple-negative breast cancer (TNBC) therapy.